1. Andresen K, Atar D, Gjertsen E, Ghanima W, Roseth S, Johansen OE. Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. Scand Cardiovasc J. 2018;523:156-62.
  2. Ficha técnica Praxbind® [actualizado 20 Noviembre 2015; citado 14 Noviembre 2019]. Disponible en:
  3. Glund S, Stangier J, Schmohl M, Moschetti V, Haazen W, De Smet M, et al. Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects. Blood. 2014;12421:344.
  4. Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, et al. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. Clin Pharmacokinet. 2017;561:41-54.
  5. Pollack CV, Jr., Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;3775:431-41.
  6. Levy JH, van Ryn J, Sellke FW, Reilly PA, Elsaesser A, Glund S, et al. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Ann Surg. 2019.
  7. Van der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S, et al. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation. 2019;1396:748-56.
  8. Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, et al. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019;7414:1760-8.
  9. Fanikos J, Murwin D, Gruenenfelder F, Tartakovsky I, Franca LR, Reilly PA, et al. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thromb Haemost. 2019.
  10. Crespo-Leiro MG, Lopez-Vilella R, Lopez Granados A, Mirabet-Perez S, Diez-Lopez C, Barge-Caballero E, et al. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain. Clin Transplant. 2019.
  11. Izquierdo García I. A multicenter experience with Idarucizumab “in real world” as reversal anticoagulation of Dabigatran. EHA Library. Jun 15, 2018;215222:PF788.
  12. Barber PA, Wu TY, Ranta A. Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort. Neurology. 2020.
  13. Ficha técnica Praxbind [updated 20 de Noviembre de 2015; cited 2018 20 de Noviembre]. Available from:
  14. EMA. Ficha técnica de Praxbind 2,5 g/ 50 ml solución inyectable y para perfusión [consultado el 8 de agosto del 2019]. 2015.